Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life. Daily subcutaneous injections with recombinant growth hormone (GH) ca...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.1040046/full |
| _version_ | 1811160282768080896 |
|---|---|
| author | Martin Bidlingmaier Beverly M.K. Biller David Clemmons Jens Otto L. Jørgensen Hiroshi Nishioka Yutaka Takahashi Yutaka Takahashi |
| author_facet | Martin Bidlingmaier Beverly M.K. Biller David Clemmons Jens Otto L. Jørgensen Hiroshi Nishioka Yutaka Takahashi Yutaka Takahashi |
| author_sort | Martin Bidlingmaier |
| collection | DOAJ |
| description | Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life. Daily subcutaneous injections with recombinant growth hormone (GH) can alleviate the abnormalities associated with AGHD. Several long-acting GH (LAGH) preparations are currently in development that aim to reduce treatment burden for patients receiving daily GH injections. Somapacitan (Sogroya®; Novo Nordisk, Denmark) is the first LAGH preparation that has been approved for treatment of AGHD in the United States, Europe, and Japan. The recent approval of somapacitan and anticipated approval of other LAGH molecules presents new questions for physicians planning to treat AGHD with LAGH in the future. Differences in the technologies used to prolong the half-life of recombinant GH are expected to result in variations in pharmacokinetic and pharmacodynamic profiles between preparations. Therefore, it is essential that physicians understand and consider such variations when treating patients with these novel GH replacement therapies. Here, we present a set of treatment recommendations that have been created to guide physicians initiating therapy with somapacitan in patients with AGHD who are eligible for GH replacement. Furthermore, we will review the published data that underlie these recommendations to explain the rationale for the treatment and monitoring advice provided. |
| first_indexed | 2024-04-10T05:54:54Z |
| format | Article |
| id | doaj.art-342be24d33884ae4b11fbb92d31b1fed |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-10T05:54:54Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-342be24d33884ae4b11fbb92d31b1fed2023-03-03T16:47:03ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-12-011310.3389/fendo.2022.10400461040046Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparationMartin Bidlingmaier0Beverly M.K. Biller1David Clemmons2Jens Otto L. Jørgensen3Hiroshi Nishioka4Yutaka Takahashi5Yutaka Takahashi6Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, GermanyNeuroendocrine & Pituitary Tumor Clinical Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United StatesDepartment of Medicine, University of North Carolina, Chapel Hill, NC, United StatesDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, DenmarkDepartment of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, JapanDepartment of Diabetes and Endocrinology, Nara Medical University, Kashihara, JapanDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, JapanAdult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life. Daily subcutaneous injections with recombinant growth hormone (GH) can alleviate the abnormalities associated with AGHD. Several long-acting GH (LAGH) preparations are currently in development that aim to reduce treatment burden for patients receiving daily GH injections. Somapacitan (Sogroya®; Novo Nordisk, Denmark) is the first LAGH preparation that has been approved for treatment of AGHD in the United States, Europe, and Japan. The recent approval of somapacitan and anticipated approval of other LAGH molecules presents new questions for physicians planning to treat AGHD with LAGH in the future. Differences in the technologies used to prolong the half-life of recombinant GH are expected to result in variations in pharmacokinetic and pharmacodynamic profiles between preparations. Therefore, it is essential that physicians understand and consider such variations when treating patients with these novel GH replacement therapies. Here, we present a set of treatment recommendations that have been created to guide physicians initiating therapy with somapacitan in patients with AGHD who are eligible for GH replacement. Furthermore, we will review the published data that underlie these recommendations to explain the rationale for the treatment and monitoring advice provided.https://www.frontiersin.org/articles/10.3389/fendo.2022.1040046/fullsomapacitangrowth hormoneadult growth hormone deficiencyinsulin-like growth factor Itreatment recommendationspharmacokinetic/pharmacodynamic modelling |
| spellingShingle | Martin Bidlingmaier Beverly M.K. Biller David Clemmons Jens Otto L. Jørgensen Hiroshi Nishioka Yutaka Takahashi Yutaka Takahashi Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation Frontiers in Endocrinology somapacitan growth hormone adult growth hormone deficiency insulin-like growth factor I treatment recommendations pharmacokinetic/pharmacodynamic modelling |
| title | Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation |
| title_full | Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation |
| title_fullStr | Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation |
| title_full_unstemmed | Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation |
| title_short | Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation |
| title_sort | guidance for the treatment of adult growth hormone deficiency with somapacitan a long acting growth hormone preparation |
| topic | somapacitan growth hormone adult growth hormone deficiency insulin-like growth factor I treatment recommendations pharmacokinetic/pharmacodynamic modelling |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.1040046/full |
| work_keys_str_mv | AT martinbidlingmaier guidanceforthetreatmentofadultgrowthhormonedeficiencywithsomapacitanalongactinggrowthhormonepreparation AT beverlymkbiller guidanceforthetreatmentofadultgrowthhormonedeficiencywithsomapacitanalongactinggrowthhormonepreparation AT davidclemmons guidanceforthetreatmentofadultgrowthhormonedeficiencywithsomapacitanalongactinggrowthhormonepreparation AT jensottoljørgensen guidanceforthetreatmentofadultgrowthhormonedeficiencywithsomapacitanalongactinggrowthhormonepreparation AT hiroshinishioka guidanceforthetreatmentofadultgrowthhormonedeficiencywithsomapacitanalongactinggrowthhormonepreparation AT yutakatakahashi guidanceforthetreatmentofadultgrowthhormonedeficiencywithsomapacitanalongactinggrowthhormonepreparation AT yutakatakahashi guidanceforthetreatmentofadultgrowthhormonedeficiencywithsomapacitanalongactinggrowthhormonepreparation |